319 related articles for article (PubMed ID: 15538111)
1. Feasibility of using tissue microarrays for the assessment of HER-2 gene amplification by fluorescence in situ hybridization in breast carcinoma.
Bhargava R; Lal P; Chen B
Diagn Mol Pathol; 2004 Dec; 13(4):213-6. PubMed ID: 15538111
[TBL] [Abstract][Full Text] [Related]
2. Chromogenic in situ hybridization for the detection of HER-2/neu gene amplification in breast cancer with an emphasis on tumors with borderline and low-level amplification: does it measure up to fluorescence in situ hybridization?
Bhargava R; Lal P; Chen B
Am J Clin Pathol; 2005 Feb; 123(2):237-43. PubMed ID: 15842048
[TBL] [Abstract][Full Text] [Related]
3. Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization.
Hammock L; Lewis M; Phillips C; Cohen C
Hum Pathol; 2003 Oct; 34(10):1043-7. PubMed ID: 14608539
[TBL] [Abstract][Full Text] [Related]
4. Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients.
Kuo SJ; Wang BB; Chang CS; Chen TH; Yeh KT; Lee DJ; Yin PL; Chen M
Taiwan J Obstet Gynecol; 2007 Jun; 46(2):146-51. PubMed ID: 17638622
[TBL] [Abstract][Full Text] [Related]
5. HER-2 status in breast cancer: correlation of gene amplification by FISH with immunohistochemistry expression using advanced cellular imaging system.
Ciampa A; Xu B; Ayata G; Baiyee D; Wallace J; Wertheimer M; Edmiston K; Khan A
Appl Immunohistochem Mol Morphol; 2006 Jun; 14(2):132-7. PubMed ID: 16785779
[TBL] [Abstract][Full Text] [Related]
6. Assessment of Her-2/neu gene amplification status in breast carcinoma with equivocal 2+ Her-2/neu immunostaining.
Mostafa NA; Eissa SS; Belal DM; Shoman SH
J Egypt Natl Canc Inst; 2011 Mar; 23(1):41-6. PubMed ID: 22099935
[TBL] [Abstract][Full Text] [Related]
7. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry.
Pauletti G; Dandekar S; Rong H; Ramos L; Peng H; Seshadri R; Slamon DJ
J Clin Oncol; 2000 Nov; 18(21):3651-64. PubMed ID: 11054438
[TBL] [Abstract][Full Text] [Related]
8. Comparative methodological analysis of erbB-2/HER-2 gene dosage, chromosomal copy number and protein overexpression in breast carcinoma tissues for diagnostic use.
Bánkfalvi A; Simon R; Brandt B; Bürger H; Vollmer I; Dockhorn-Dworniczak B; Lellé RJ; Boecker W
Histopathology; 2000 Nov; 37(5):411-9. PubMed ID: 11119122
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine kinase activation in breast carcinoma with correlation to HER-2/neu gene amplification and receptor overexpression.
Bhargava R; Naeem R; Marconi S; Luszcz J; Garb J; Gasparini R; Otis CN
Hum Pathol; 2001 Dec; 32(12):1344-50. PubMed ID: 11774167
[TBL] [Abstract][Full Text] [Related]
10. Assessment of HER-2/neu overexpression and/or gene amplification in breast carcinomas: should in situ hybridization be the method of choice?
Sauer T; Wiedswang G; Boudjema G; Christensen H; Karesen R
APMIS; 2003 Mar; 111(3):444-50. PubMed ID: 12752225
[TBL] [Abstract][Full Text] [Related]
11. Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization.
Lebeau A; Deimling D; Kaltz C; Sendelhofert A; Iff A; Luthardt B; Untch M; Löhrs U
J Clin Oncol; 2001 Jan; 19(2):354-63. PubMed ID: 11208826
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical detection of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 in formalin-fixed breast carcinoma cell block preparations: correlation of results to corresponding tissue block (needle core and excision) samples.
Kinsella MD; Birdsong GG; Siddiqui MT; Cohen C; Hanley KZ
Diagn Cytopathol; 2013 Mar; 41(3):192-8. PubMed ID: 22611048
[TBL] [Abstract][Full Text] [Related]
13. c-erbB-2 (HER-2/neu) immunohistochemistry in invasive breast cancer: is there concordance between standard sections and tissue microarrays?
Selvarajan S; Tan SY; Sii LH; Tan PH
Pathology; 2006 Aug; 38(4):316-20. PubMed ID: 16916720
[TBL] [Abstract][Full Text] [Related]
14. HER-2/neu analysis in breast cancer bone metastases.
Zustin J; Boddin K; Tsourlakis MC; Burandt E; Mirlacher M; Jaenicke F; Izbicki J; Ruether W; Rueger JM; Bokemeyer C; Simon R; Sauter G
J Clin Pathol; 2009 Jun; 62(6):542-6. PubMed ID: 19474354
[TBL] [Abstract][Full Text] [Related]
15. Real-time quantitative PCR of microdissected paraffin-embedded breast carcinoma: an alternative method for HER-2/neu analysis.
Gjerdrum LM; Sorensen BS; Kjeldsen E; Sorensen FB; Nexo E; Hamilton-Dutoit S
J Mol Diagn; 2004 Feb; 6(1):42-51. PubMed ID: 14736826
[TBL] [Abstract][Full Text] [Related]
16. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization.
Jimenez RE; Wallis T; Tabasczka P; Visscher DW
Mod Pathol; 2000 Jan; 13(1):37-45. PubMed ID: 10658908
[TBL] [Abstract][Full Text] [Related]
17. Detection of HER-2/neu (c-erb B-2) DNA amplification in primary breast carcinoma. Interobserver reproducibility and correlation with immunohistochemical HER-2 overexpression.
Tsuda H; Akiyama F; Terasaki H; Hasegawa T; Kurosumi M; Shimadzu M; Yamamori S; Sakamoto G
Cancer; 2001 Dec; 92(12):2965-74. PubMed ID: 11753973
[TBL] [Abstract][Full Text] [Related]
18. Assessment of HER2/Neu status by fluorescence in situ hybridization in immunohistochemistry-equivocal cases of invasive ductal carcinoma and aberrant signal patterns: a study at a tertiary cancer center.
Murthy SS; Sandhya DG; Ahmed F; Goud KI; Dayal M; Suseela K; Rajappa SJ
Indian J Pathol Microbiol; 2011; 54(3):532-8. PubMed ID: 21934215
[TBL] [Abstract][Full Text] [Related]
19. HER2 positivity in breast carcinoma: a comparison of chromogenic in situ hybridization with fluorescence in situ hybridization in tissue microarrays, with targeted evaluation of intratumoral heterogeneity by in situ hybridization.
Loring P; Cummins R; O'Grady A; Kay EW
Appl Immunohistochem Mol Morphol; 2005 Jun; 13(2):194-200. PubMed ID: 15894935
[TBL] [Abstract][Full Text] [Related]
20. HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of HercepTest and PathVysion commercial assays.
McCormick SR; Lillemoe TJ; Beneke J; Schrauth J; Reinartz J
Am J Clin Pathol; 2002 Jun; 117(6):935-43. PubMed ID: 12047146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
